Skip to main content
Top
Published in: Lung 3/2015

01-06-2015

The Ratio of Free to Bound Desmosine and Isodesmosine May Reflect Emphysematous Changes in COPD

Authors: Xingjian Liu, Shuren Ma, Sophie Liu, Ming Liu, Gerard Turino, Jerome Cantor

Published in: Lung | Issue 3/2015

Login to get access

Abstract

Background

The unique elastin crosslinks, desmosine and isodesmosine (DID) are significantly elevated in blood, urine, and sputum from patients with COPD, and may decline following treatment of the disease. However, the large degree of variance in this biomarker among COPD patients with similar levels of disease suggests that it has limited prognostic value with regard to the degree of lung disease in a given individual. As an alternative to measuring the total amount of DID, we propose using the ratio of free to peptide-bound DID, which may provide a better indication of overall lung disease.

Methods

To test this hypothesis, the free/bound DID ratio was measured in bronchoalveolar lavage fluid (BALF) from both hamsters with elastase-induced emphysema and controls not given the enzyme, using a combination of liquid chromatography and tandem mass spectroscopy. This ratio was then correlated with airspace enlargement, as measured by the mean percentage of lung surface area at ×100 microscopic magnification.

Results

There was a significant negative correlation between the free/bound DID ratio in BALF and lung surface area. However, there was no correlation between this ratio and total BALF DID, suggesting that free/bound DID is unrelated to the immediate rate of breakdown of elastic fibers, and may instead measure the cumulative effect of elastase injury in the lung.

Conclusions

The free/bound DID ratio may be a useful measure of emphysematous changes in the lung and might also serve as a screening procedure for healthy smokers and other individuals at risk for developing COPD.
Literature
1.
go back to reference Hogg JC, Timens W (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4:435–459CrossRefPubMed Hogg JC, Timens W (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4:435–459CrossRefPubMed
2.
4.
go back to reference Turino GM, Lin YY, He J et al (2012) Elastin degradation: an effective biomarker in COPD. COPD 9:435–438PubMed Turino GM, Lin YY, He J et al (2012) Elastin degradation: an effective biomarker in COPD. COPD 9:435–438PubMed
5.
go back to reference Lindberg CA, Engström G, de Verdier MG et al (2012) Total desmosines in plasma and urine correlate with lung function. Eur Respir J 39:839–845CrossRefPubMed Lindberg CA, Engström G, de Verdier MG et al (2012) Total desmosines in plasma and urine correlate with lung function. Eur Respir J 39:839–845CrossRefPubMed
6.
go back to reference Ma S, Turino GM, Lin YY (2011) Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. J Chromatogr B 879:1893–1898CrossRef Ma S, Turino GM, Lin YY (2011) Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. J Chromatogr B 879:1893–1898CrossRef
7.
go back to reference Fregonese L, Ferrari F, Fumagalli M et al (2011) Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antitrypsin deficiency-related COPD. COPD 8:329–333CrossRefPubMed Fregonese L, Ferrari F, Fumagalli M et al (2011) Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antitrypsin deficiency-related COPD. COPD 8:329–333CrossRefPubMed
8.
go back to reference Luisetti M, Ma S, Iadarola P et al (2008) Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 32:1146–1157CrossRefPubMed Luisetti M, Ma S, Iadarola P et al (2008) Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 32:1146–1157CrossRefPubMed
9.
go back to reference Ma S, Lin YY, Turino GM (2007) Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest 131:1363–1371CrossRefPubMed Ma S, Lin YY, Turino GM (2007) Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest 131:1363–1371CrossRefPubMed
10.
go back to reference Stauffer D, Aharony A (2001) Introduction to percolation theory, 2nd edn (revised). Taylor and Francis, Philadelphia Stauffer D, Aharony A (2001) Introduction to percolation theory, 2nd edn (revised). Taylor and Francis, Philadelphia
11.
go back to reference Cantor JO, Ma SM, Turino GM (2013) What percolation theory can tell us about COPD. Med Hypotheses 81:152–155CrossRefPubMed Cantor JO, Ma SM, Turino GM (2013) What percolation theory can tell us about COPD. Med Hypotheses 81:152–155CrossRefPubMed
12.
go back to reference Li B, Daggett V (2002) Molecular basis for the extensibility of elastin. J Muscle Res Cell Motil 23:561–573CrossRefPubMed Li B, Daggett V (2002) Molecular basis for the extensibility of elastin. J Muscle Res Cell Motil 23:561–573CrossRefPubMed
13.
go back to reference Kielty CM, Sherratt MJ, Shuttleworth CA (2002) Elastic fibres. J Cell Sci 115:2817–2828PubMed Kielty CM, Sherratt MJ, Shuttleworth CA (2002) Elastic fibres. J Cell Sci 115:2817–2828PubMed
14.
go back to reference Bunde A, Kantelhart JW (2005) Diffusion and conduction in percolation systems. In: Heitjans P, Karger J (eds) Diffusion in condensed matter. Springer, Berlin, pp 895–914CrossRef Bunde A, Kantelhart JW (2005) Diffusion and conduction in percolation systems. In: Heitjans P, Karger J (eds) Diffusion in condensed matter. Springer, Berlin, pp 895–914CrossRef
15.
go back to reference Redner S (2009) Fractal and multifractal scaling of electrical conduction in random resistor networks. In: Meyers PA (ed) Encyclopedia of complexity and systems science. Springer, Berlin, pp 3737–3754CrossRef Redner S (2009) Fractal and multifractal scaling of electrical conduction in random resistor networks. In: Meyers PA (ed) Encyclopedia of complexity and systems science. Springer, Berlin, pp 3737–3754CrossRef
16.
go back to reference Sander LM, Warren CP, Sokolov IM et al (2002) Percolation on heterogeneous networks as a model for epidemics. Math Biosci 180:293–305CrossRefPubMed Sander LM, Warren CP, Sokolov IM et al (2002) Percolation on heterogeneous networks as a model for epidemics. Math Biosci 180:293–305CrossRefPubMed
17.
go back to reference Sahimi M (2009) Percolation phase transition. In: Meyers PA (ed) Encyclopedia of complexity and systems science. Springer, Berlin, pp 6538–6545CrossRef Sahimi M (2009) Percolation phase transition. In: Meyers PA (ed) Encyclopedia of complexity and systems science. Springer, Berlin, pp 6538–6545CrossRef
19.
go back to reference Bates JH, Davis GS, Majumdar A et al (2007) Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med 176:617–623CrossRefPubMedCentralPubMed Bates JH, Davis GS, Majumdar A et al (2007) Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med 176:617–623CrossRefPubMedCentralPubMed
20.
go back to reference Murphy KD, Hunt GW, Almond DP (2006) Evidence of emergent scaling in mechanical systems. Philos Mag 86:3325–3338CrossRef Murphy KD, Hunt GW, Almond DP (2006) Evidence of emergent scaling in mechanical systems. Philos Mag 86:3325–3338CrossRef
21.
go back to reference Jesudason R, Black L, Majumdar A et al (2007) Differential effects of static and cyclic stretching during elastase digestion on the mechanical properties of extracellular matrices. J Appl Physiol 103:803–811CrossRefPubMed Jesudason R, Black L, Majumdar A et al (2007) Differential effects of static and cyclic stretching during elastase digestion on the mechanical properties of extracellular matrices. J Appl Physiol 103:803–811CrossRefPubMed
22.
go back to reference Doyle TJ, Pinto-Plata V, Morse D et al (2012) The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest 142:1027–1034CrossRefPubMedCentralPubMed Doyle TJ, Pinto-Plata V, Morse D et al (2012) The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest 142:1027–1034CrossRefPubMedCentralPubMed
23.
go back to reference Rosenberg SR, Kalhan R (2012) Biomarkers in chronic obstructive pulmonary disease. Transl Res 159:228–237CrossRefPubMed Rosenberg SR, Kalhan R (2012) Biomarkers in chronic obstructive pulmonary disease. Transl Res 159:228–237CrossRefPubMed
Metadata
Title
The Ratio of Free to Bound Desmosine and Isodesmosine May Reflect Emphysematous Changes in COPD
Authors
Xingjian Liu
Shuren Ma
Sophie Liu
Ming Liu
Gerard Turino
Jerome Cantor
Publication date
01-06-2015
Publisher
Springer US
Published in
Lung / Issue 3/2015
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-015-9712-z

Other articles of this Issue 3/2015

Lung 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.